Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) CEO Sells $19,162.00 in Stock

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) CEO John Valliant sold 2,600 shares of the company’s stock in a transaction on Monday, April 11th. The shares were sold at an average price of $7.37, for a total value of $19,162.00. Following the completion of the sale, the chief executive officer now owns 358,379 shares of […]

Related Keywords

John Valliant ,Fusion Pharmaceuticals Inc ,Geode Capital Management ,Securities Exchange Commission ,Goldman Sachs Group Inc ,Zacks Investment Research ,Sectoral Asset Management Inc ,Nasdaq ,Fusion Pharmaceuticals Get Rating ,Alphacentric Advisors ,Quarter For Fusion Pharmaceuticals ,Fusion Pharmaceuticals ,Millennium Management ,Get Rating ,Exchange Commission ,Sachs Group ,Capital Management ,Asset Management Inc ,Investment Research ,Pharmaceuticals Inc ,Targeted Alpha Therapies ,Nasdaq Fusn ,Fusn ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,